Zyprexa

Wilderbeek said he hoped to provide investors with some data on pivotal Phase III clinical studies of the medicine later in the year.

Shares in Akzo Nobel were 2.2 percent lower at 44.30 euros by 1345 GMT, after hitting their highest level in nearly four years on Friday, helped by M&A activity in the European sector after Bayer (BAYG.DE: Quote, Profile, Research) agreed to buy Schering (SCHG.DE: Quote, Profile, Research).

"There's nothing new on Akzo's filing plans.

Also, shares were up last week on news about Bayer and Schering.

There may be some profit taking today," one trader in Amsterdam said.

Among other products, Akzo is currently awaiting U.S.

approval for its contraceptive drug Implanon and hormone therapy drug Livial, and expects to submit sugammadex used in anaesthesia next year.

A new fertility product, Org 36286, is planned for submission in 2008 - a delay from 2007 - and a new contraceptive NOMAC/E2 is expected to be filed in 2009.

A filing for an insomnia treatment Org 50081 is planned in 2010 - a delay from 2008.

Continued ...

© Reuters 2006.

All Rights Reserved.

1 RSS About Re...

Read more...